CancerLinQ partners with FDA to study real-world use of newly approved cancer treatments

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CancerLinQ LLC, an initiative of the American Society of Clinical Oncology, announced a long-term partnership with FDA that will rely on cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login